The characterisation of disorders associated with extreme pre-and postnatal growth restriction allows the identification of novel human growth regulators. This has been demonstrated by studies of microcephalic osteodysplastic primordial dwarfism type II with the identification of mutations in pericentrin (PCNT) , signifying the importance to human growth of the mitotic spindle in regulating normal chromosome segregation [1] .
Through the study of molecular defects of the primordial growth disorder 3-M syndrome (MIM 273750 and 612921), we have identified a novel pathway controlling human growth. 3-M syndrome is a distinct growth disorder first described by Miller, McKusick and Malvaux in 1975 , with the name derived from the shared initial letter of the authors' surnames [2] . 3-M syndrome is characterised by prenatal growth restriction in the absence of recognisable maternal or placental pathology and by the failure of postnatal catch-up growth resulting in significant proportionate short stature without associated microcephaly often seen in microcephalic osteodysplastic primordial dwarfism type II.
Silver-Russell syndrome (SRS), a severe short stature condition with a high degree of phenotypic overlap with 3-M syndrome, should be considered in the differential diagnosis. There have been over 400 reported cases of SRS [3] . The key diagnostic characteristics of SRS include a birth weight ! -2 standard deviation score (SDS), postnatal growth restriction, normal head circumference, triangular-shaped face with a broad forehead and a pointed, small chin with a wide, thin mouth and body asymmetry [4] . Patton [5] proposed that the slender long bones and tall vertebrae in 3-M syndrome are important in distinguishing between the two conditions. However, many 3-M syndrome patients do not show these features, suggesting that this should probably not be used for differential diagnosis. Learning difficulties can be a part of SRS but are not seen in 3-M syndrome, whereas prominent heels, a fleshy protrusion on the back of the heel, are an almost universal feature in 3-M syndrome patients but not in SRS patients ( table 1 ) .
Genetics of Silver-Russell Syndrome
SRS is genetically heterogeneous and often sporadic [17] , and around 60% of cases are associated with genetic abnormalities: approximately 50% have imprinting abnormalities on chromosome 11p15, while approximately 10% demonstrate uniparental disomy of chromosome 7 (UPD7) [18] .
Hypomethylation of the insulin like growth factor II (IGF-II) and H19 imprinting centre at 11p15 has recently been associated with SRS [19] . While loss of DNA methylation of this site results in an SRS phenotype, hypermethylation of the same site results in the overgrowth syndrome Beckwith-Wiedemann [19] . Eggermann et al. [20] , Gicquel et al. [21] and Eggermann [22] showed that a number of patients exhibiting an SRS phenotype have a maternal 11p15 duplication that leads to loss of IGF-II expression and concomitant short stature.
UPD7 involves maternal chromosome regions 7p12-p14 and 7q31-qter [23] . The region at chromosome 7p12-p14 contains a number of imprinted candidate genes including GRB10 , IGFBP1 and IGFBP3 . Mutation analysis of GRB10 , however, has not revealed any pathogenic variants in SRS patients [3] . The causative gene in the region 7q31-qter has likewise not been identified [17] .
Clinical Features of 3-M Syndrome
The main clinical features of 3-M syndrome are severe postnatal growth restriction with normal but recognisable facial features including triangular face, flat maxillae and prominent forehead. Other facial features include a fleshy tipped nose, pointed chin and long philtrum [2, 13, 14] . Skeletal abnormalities including relatively tall vertebrae and slender long bones are seen with variable frequency [13, 24, 25] . Other features commonly associated with 3-M syndrome are a short neck, winged scapulae, short thorax, transverse chest groove, hyperlordosis, developmental dysplasia hip and spina bifida occulta [2, 8, [12] [13] [14] [15] [24] [25] [26] . In younger patients, prominent heels are an almost universal feature, particularly in those with a genetic diagnosis. Unlike many other short stature conditions, 3-M syndrome is associated with normal intelligence and developmental milestones are achieved. Adult height is in the range of 115 to 150 cm (-8 to -4 SD) ( fig. 1 ) [10] . 
Genetics of 3-M Syndrome
The initial 3-M syndrome locus was identified on 6p21.1, and subsequent candidate analysis of the region revealed that mutations in the cullin 7 gene (CUL7) cause 3-M syndrome [10] . As part of that investigation, we identified a smaller subset of patients who did not carry CUL7 mutations but appeared to present with an identical phenotype ( fig. 1 ). Further autozygosity mapping revealed a second locus located on 2q35 with mutations in the gene encoding for obscurin-like 1 (OBSL1) found to be the underlying cause [24] . In addition, a number of patients have neither CUL7 nor OBSL1 mutations, and exome sequencing in 3 such patients revealed that mutations in the coiled-coil domain containing protein 8 (CCDC8) cause the 3-M syndrome [27] .
CUL7 Mutations Cause 3-M Syndrome
Huber et al. [10] performed autozygosity mapping with seven consanguineous 3-M syndrome families of Tunisian, Moroccan and French descent. This revealed a 3.84-Mb homozygous region shared by all seven families on chromosome 6p21.1. In addition, all four Tunisian families shared a 0.47-Mb region of common haplotype indicating the location of the candidate gene. Subsequent analysis revealed pathogenic mutations within CUL7. CUL7 mutations are found throughout the whole gene, although approximately half of the mutations are located in the cullin domain. The majority of CUL7 mutations cause premature termination and are therefore likely to lead to complete loss of the CUL7 protein; however, a small number are missense mutations and thus predicted to lead to the generation of a nonfunctional protein product ( fig. 2 ) [10, 25, 28] .
3-M syndrome shares a high degree of similarity with two other short stature conditions: gloomy face syn- drome [26] and the recently identified Yakut short stature syndrome [25] . Both have the same genetic cause as 3-M syndrome and are therefore unlikely to be separate entities, but rather to be part of a wider 3-M syndrome spectrum. Huber et al. [10] suggested the inclusion of gloomy face into 3-M syndrome following similarities in longterm follow-up and, most importantly, the identification of mutations in CUL7 in both sets of patient. Maksimova et al. [25] reported that the Yakut short stature syndrome patients suffered variable neonatal respiratory distress that had not been previously recognised as a feature of 3-M syndrome. However, other clinical features and characteristics of 3-M syndrome and identification of mutations in CUL7 would suggest that the Yakut short stature syndrome patients actually have 3-M syndrome.
CUL7 and the Ubiquitin-Proteasome Pathway
The protein product CUL7 is the most recently defined member of the cullin family and is an integral part of the ubiquitin-proteasome pathway acting as a structural protein in the formation of a SKP1-CUL7-FBXW8-ROC1 (SCF) E3 ubiquitin ligase complex [29] .
The ubiquitin-proteasome pathway is a major protein degradation pathway in which proteins are targeted for degradation, a process which involves attachment of ubiquitin to a target protein by the E3 ubiquitin ligase complex followed by degradation by the 26S proteasome. The roles of SCF complexes and the ubiquitination system have been reviewed previously [30] .
Unlike other cullin proteins which can interact with several F-box proteins to form alternative SCF complexes, FBXW8 is currently the only F-box protein known to interact with CUL7 ( fig. 3 ). In keeping with the clinical feature of 3-M syndrome, targeted disruption of Cul7 in mice resulted in intrauterine growth restriction (IUGR) and placental abnormalities. Arai et al. [31] showed that Cul7 -/-embryos survived to embryonic day 18.5 but did not survive birth. In addition to the severe growth restriction seen, Cul7 -/-embryos were unable to breathe unaided, and it was shown that the lungs had markedly reduced alveolar space compared to wild type [31] . Although a 3-M syndrome foetus with a CUL7 mutation had no obvious alveolar abnormalities, there was insufficient development of the cartilaginous lamina, which may explain the respiratory distress that was seen in a subset of the Yakut 3-M syndrome patients [25] . The Cul7 -/-phenotype is similar to that exhibited by Fbxw8 -/-mice with severe growth restriction and some respiratory failure [32] . Fbxw8 -/-mice have a reduced placental size but appear to have no isolated placental abnormalities. Tsutsumi et al. [33] confirmed the Fbxw8 -/-phenotype and underlined the similarities between Fbxw8 -/-and Cul7 -/-mice. Growth restriction of Fbxw8 -/-mice continued postnatally, but the mice were otherwise normal. Arai et al. [31] phenotype of mice which lack Cul7 compared to Fbxw8 is especially evident as 30% of Fbxw8 -/-mice survive birth. This would suggest that Cul7 has further cellular functions that are not shared with Fbxw8 [32, 34] .
CUL7 Interaction Network
To date, there is limited data regarding the known proteolytic targets of the CUL7 SCF complex. Two studies have shown the F-box component of the CUL7 SCF complex, FBXW8 interacts with and targets the degradation of cyclin D1 [35] and insulin receptor substrate 1 (IRS-1) [36] .
Cyclin D1
The role of cyclin D1 as an important regulator of cell cycle progression and its role in cancer due to aberrant expression have been previously reviewed [37] . Okabe et al. [35] demonstrated that cyclin D1 associates with FBXW8 -an interaction dependent on MAPK-mediated T286 phosphorylation suggesting that the CUL7 SCF complex is responsible for cyclin D1 ubiquitination. However, further evidence that multiple SCF complexes are responsible for cyclin D1 ubiquitination and subsequent degradation makes it difficult to determine the importance of FBXW8/CUL7-mediated cyclin D1 degradation to cell cycle regulation [38] .
IRS-1
IRS-1 is a member of a family of proteins that act as adaptor proteins in both the insulin and IGF-I signalling cascades and are involved in numerous biological pathways [39] . In 2008, Xu et al. [36] performed a proteomic analysis to discover potential targets of the CUL7 SCF complex by using a stable FBXW8-expressing cell line to immunoprecipitate interacting partners and thus probable substrate proteins. This led to the identification of IRS-1 as a proteolytic target of the CUL7 SCF complex [36] . IRS-1 binds to the insulin or IGF-I receptors and is phosphorylated at the tyrosine-rich C-terminal region. SH-2 domain-containing proteins are then recruited, leading to the activation of downstream pathways including AKT and MAPK/ERK [39] . Xu et al. [36] of IRS-1 may activate CUL7-mediated cellular senescence, which may in part explain the growth restriction seen in 3-M syndrome patients [36] .
Non-Proteolytic Function of CUL7
Atypical of other cullin proteins, CUL7 also contains a CPH domain (a conserved region found in C UL7/ P ARC/ H ERC2) [40] . This domain is responsible for some non-proteolytic functions of CUL7, including acting as a p53 binding region and, although the CUL7 E3 ligase is not responsible for the degradation of p53, it may participate in its activation and cellular localisation [40] [41] [42] [43] . Whether CUL7 contributes to p53-dependent apo ptosis remains to be fully determined; however, Kim et al. [44] demonstrated that CUL7 expression prevents c-Myc-and N-Myc-mediated apoptosis in a p53-dependent manner.
OBSL1 Mutations Cause 3-M Syndrome
In a large cohort of 3-M syndrome patients who did not carry CUL7 mutations, we performed autozygosity mapping revealing a second 3-M syndrome locus located at chromosome 2q35-q36.1, spanning 5.7 Mb. Further haplotype analysis refined the critical region to a 1.27-Mb region. Pathogenic mutations were subsequently identified in the OBSL1 gene, of which all were presumptive null mutations [24] . Huber et al. [45] also identified OBSL1 mutations in a separate cohort of 3-M syndrome patients, including the identification of the first OBSL1 missense mutation ( fig. 4 ) .
To date, approximately 65% of mutations described in 3-M syndrome patients are found in CUL7 , with 30% identified in OBSL1 [10, 24, 25, 28, 45] .
OBSL1 Structure and Function
OBSL1 is related to the giant muscle protein obscurin [46] . Gene duplication and rearrangement of obscurin resulted in the formation of two genes: SPEG (striated muscle preferentially expressed gene) and OBSL1 . SPEG was first identified as a serine/threonine kinase with isoforms expressed in smooth, skeletal and heart muscle as well as brain tissue [47] . It was subsequently found that SPEG shared its arrangement of these kinase domains with obscurin [48] . OBSL1 was identified by Geisler et al.
[46] and is located within 100 kb of SPEG on chromosome 2q35. The fibronectin domain of OBSL1 is most closely related to the fibronectin domain at the aminoterminal of obscurin [46] . Previously, Sutter et al. [48] showed that the carboxy fibronectin domain of obscurin closely resembled the fibronectin domain of SPEG. Also, SPEG is transcribed by the forward strand of chromo -1  2  3  4  5  6  7  8  9  10  11 12  13  14  15  16  17  18  19  20  21  22 Isoform some 2, whereas OBSL1 is transcribed by the reverse strand. Therefore, the duplication event of obscurin that gave rise to OBSL1 and SPEG also resulted in a genomic rearrangement. OBSL1 exists as three groups of isoforms A, B and C that share a common translational start site which is also conserved between human, mouse and rat [46] . The variability of the three OBSL1 isoforms is derived from the use of alternative stop codons. Geisler et al.
[46] identified a number of different transcripts ranging in size from 3.3 to 5.9 kb. All OBSL1 isoforms share a common aminoterminal region consisting of four Ig domains and a fibronectin domain. The smaller transcripts encode three carboxy-terminal Ig domains, whereas the longest known transcript of isoform A encodes thirteen carboxy-terminal Ig domains [46] . Interestingly, Fukuzawa et al. [49] have suggested that further differentially spliced variants of OBSL1 exist. Three human expressed sequence tags have been identified in which the first coding exon is missing (DA680669, BX381924 and DA427488), suggesting the possible use of one of two alternative translational start sites located in exon 3, both in the same reading frame as the original translational start site. The potential new alternative translational start site residues would correspond to p.M413 and p.M479 of the current OBSL1 isoforms.
Cellular localisation studies carried out in adult rat cardiac myocytes revealed that OBSL1 is found at the intercalated discs, the perinuclear region and the Z lines with low level expression at the M bands [46] . During remodelling of myocytes to form new sarcomeres, OBSL1 localises to the perinuclear region but dissociates from both the Z lines and M bands [46] . Geisler et al.
[46] also suggested that OBSL1 remains associated with the nuclear envelope and surrounding cytoskeletal network, but that this is dependent on the morphology of the nucleus.
OBSL1 is composed entirely of Ig-like domains with a single fibronectin domain. These domains have been previously identified in titin, myomesin and obscurin in which they play a role in protein-protein interaction [46] . Due to the cellular localisation in cardiac myocytes and the predicted domain structure of OBSL1, Geisler et al. [46] postulated that OBSL1 may function as a cytoskeletal adaptor protein linking membrane-bound nuclear proteins to the cytoplasmic support network. Since Geisler et al.
[46] also found that OBSL1 was expressed in a wide variety of cell types, it is possible that OBSL1 may have a broader role as a scaffolding protein. During the investigation by Fukuzawa et al. [49] , the N-terminal region of obscurin was found to interact with both titin and myomesin; at the same time, interaction between these two proteins and OBSL1 was also established. Similar to obscurin, it was found that the N-terminal region of OBSL1, which is homologous to the N-terminal region of obscurin, is also responsible for the interaction with titin and myomesin [49] [50] [51] . Fukuzawa et al. [49] assumed that since OBSL1 lacks any of the signalling domains of obscurin, its primary role would be as a structural protein.
Both Geisler et al.
[46] and Fukuzawa et al. [49] postulated that the involvement of OBSL1 as a key component of the cytoskeletal network indicated a role in the progression of myopathies. Fukuzawa et al. [49] suggested that this would be due to loss of titin interaction at the M lines of sarcomeres. However, our recent report identifying OBSL1 mutations as a cause of 3-M syndrome indicated a broader role for OBSL1 in the CUL7 ubiquitination pathway [24] . Currently, there is only rudimentary knowledge of OBSL1 and it is clear that further characterisation is required to elucidate the function of OBSL1 and specifically its impact on the regulation of human growth. To date, we did not identify muscle weakness as a feature of 3-M syndrome.
CCDC8 Mutations Cause 3-M Syndrome
We and others have reported some cases of 3-M syndrome patients who have neither CUL7 nor OBSL1 mutations, suggesting involvement of further genes [24, 45] . We recently identified mutations in CCDC8 in a small cohort of 3-M syndrome patients. Two different mutations have so far been identified in five unrelated families and both result in the generation of a premature stop codon and subsequent loss of function. We demonstrated by immunoblotting that a 3-M syndrome patient with a CCDC8 mutation had no detectable CCDC8 protein and that 3-M syndrome patients with either CUL7 or OBSL1 mutations had normal levels of CCDC8 protein [27] .
Elucidating the 3-M Syndrome Pathway
Thus, three apparently unrelated cytoplasmic proteins have been implicated in the pathogenesis of the human growth disorder 3-M syndrome: one an ubiquitin ligase (CUL7), one a cytoskeletal adaptor (OBSL1) and one a protein of undefined function (CCDC8). In the current literature, 94 families have a genetic confirmation of 3-M syndrome: 63 families have CUL7 mutations, 26 OBSL1 mutations and 5 CCDC8 mutations. We have previously shown that loss of OBSL1 by siRNA also leads to reduction of CUL7 expression, suggesting the two proteins may be linked [24] . However, it appears that the loss of either CUL7 or OBSL1 in patient-derived cells does not affect CCDC8 levels. Co-immunoprecipitation assays revealed that CCDC8 and OBSL1 physically interact, while, at the same time, OBSL1 and CUL7 interact; however, in this system CCDC8 and CUL7 do not appear to directly associate [27] . The identification of three different genes associated with the same growth disorder and the associated physical interactions between the three proteins would suggest that they exist within a common biochemical pathway.
How Does Disruption of the CUL7/OBSL1 Pathway Lead to Growth Restriction?
Murine models of Cul7 and Fbxw8 disruption exhibit an impairment of growth, and cell lines derived from these animal models demonstrate a reduction in cell proliferation and induction of senescence [31, 33, 36] . It is likely that the primary mechanism responsible for the growth restriction seen in knockout mouse models and in 3-M syndrome patients is the disruption of the CUL7 SCF complex. The downstream effects of this disruption result in a failure of IRS-1 ubiquitination and proteolysis, thus leading to cellular accumulation of IRS-1.
Alteration of the IGF-I pathway has long been shown to result in severe growth restriction in mouse knockout models [52] [53] [54] . The apparent accumulation of IRS-1 leads to the activation of the AKT and MAPK pathways. It is postulated that the overstimulation of these pathways ultimately leads to induction of cellular senescence [36] , which in turn could result in poor growth explaining the growth restriction of 3-M syndrome patients.
Future studies should be directed at the identification of the remaining members of this pathway and how this novel pathway controls cell growth. For instance, it is currently unclear as to how OBSL1 interacts with the IGF-I signalling pathway; however, it may function as a structural protein linking CUL7 to IRS-1. The identification of further genes causing 3-M syndrome is likely to reveal other proteins in this pathway.
The importance of this pathway extends beyond human growth in that CUL7 has been implicated in cancer. It has been shown in a number of studies that the expression of SCF complexes, notably CUL1 (reviewed in [55] ) and CUL7 [44] , are elevated in a number of malignant tumours, but it may be that loss of CUL7 and/ or associated proteins is in fact cancer protecting. Thus, understanding the key interactions between CUL7, OBSL1, CCDC8 and IGF signalling may have implications both for statural growth and dysregulated cellular growth.
